{
    "clinical_study": {
        "@rank": "104082", 
        "arm_group": [
            {
                "arm_group_label": "EPO group", 
                "arm_group_type": "Experimental", 
                "description": "EPO group received 300 IU/kg of rHuEPO-alpha  via intravenous bolus administration after induction of anesthesia."
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo group received normal saline via intravenous bolus administration after induction of anesthesia."
            }
        ], 
        "brief_summary": {
            "textblock": "Acute kidney injury (AKI) frequently occurs after cardiac surgery using cardiopulmonary\n      bypass (CPB). Recombinant human erythropoietin (rHuEPO) is known to provide organ protection\n      against ischemia-reperfusion injury through its anti-inflammatory properties. The aim of the\n      present study was to investigate the effect of a single preoperative bolus of EPO on the\n      incidence of AKI following complex valvular heart surgery in a randomized, controlled and\n      double-blind trial."
        }, 
        "brief_title": "Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Acute Kidney Injury", 
        "condition_browse": {
            "mesh_term": [
                "Acute Kidney Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  preoperative risk factors for AKI and scheduled for complex valvular heart operations\n\n          -  Enrolled criteria for high risk of AKI were patients with more than 2 of bellows:\n             female,  serum creatinine >1.2 mg/dl, preoperative A-fib, GFR < 60 ml/min, NYHA class\n             IV, HTN, DM, age > 65 years, peripheral vascular disease.\n\n          -  Complex valvular heart operations were defined as double-valve surgery, combined\n             valve and coronary artery bypass grafting procedures, Bentall operation, combined\n             mitral valve surgery and tricuspid annuloplasty or reoperation.\n\n        Exclusion Criteria:\n\n          -  Patients with preexisting uncontrolled hypertension (diastolic blood pressure > 100\n             mmHg), immunosuppression, history of thromboembolism, malignant disease, seizure,\n             liver dysfunction, renal impairment (serum creatinine > 2 mg/dL), and drug or alcohol\n             abuse were excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "98", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758861", 
            "org_study_id": "4-2011-0355"
        }, 
        "intervention": [
            {
                "arm_group_label": "EPO group", 
                "intervention_name": "EPO group", 
                "intervention_type": "Drug", 
                "other_name": "EPO group received 300 IU/kg of rHuEPO-alpha  via intravenous bolus administration after induction of anesthesia."
            }, 
            {
                "arm_group_label": "Placebo group", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Epoetin Alfa"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Erythropoietin", 
            "acute kidney injury", 
            "valvular heart surgery"
        ], 
        "lastchanged_date": "December 31, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Department of anesthesiology and pain medicine Yonsei University College of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The diagnostic criteria for AKI is followed by AKIN criteria (absolutely increase in the SCr concentration \u2265 0.3 mg/dL from baseline, \u2265 50% increase in the SCr concentration within 48 hours after operation).", 
            "measure": "incidence of acute kidney injury", 
            "safety_issue": "No", 
            "time_frame": "change of renal function including SCr, cystatin C, creatinine clearance from 24 h before operation to postoperative day (POD) 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}